- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
Keynote Lecture: Cell transfer immunotherapy targeting unique somatic mutations in cancer
Steven A. Rosenberg
National Cancer Inst., Bethesda, MD, United States
- Free
- slides video
- audio + slides
- All slides included
Resistance to PD-1 blockade in melanoma
Antoni Ribas
UCLA Medical Ctr., Los Angeles, CA, United States
- Free
- slides video
- audio + slides
- All slides included
Leveraging clinical genomics for candidate neoantigen discovery
Eliezer M. Van Allen
Dana-Farber Cancer Inst., Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Navigating the known and unknown challenges in the development of a selective NTRK inhibitor: The larotrectinib story
Keith T Flaherty
Massachusetts General Hosp. Cancer Ctr., Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Job's dilemma for the genome: Why bad things happen to good chromosomes
David Pellman
Dana-Farber Cancer Institute, Boston, MA, United States
- Free
- audio + slides
- Some slides withheld
DNA damage signatures and practical use
Serena Nik-Zainal
Wellcome Trust Sanger Inst., Cambridge, United Kingdom
- Free
- slides video
- audio + slides
- All slides included
Leveraging the power of collaboration in a genomics tumor board: None of us is as smart as all of us
Janessa Laskin
BC Cancer Agency, Vancouver, BC, Canada
- Free
- slides video
- audio + slides
- All slides included
gMSK-IMPACT: Tumor/normal sequencing to guide diagnosis, treatment selection, and clinical trial enrollment
Michael F. Berger
Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Free
- Unknown permission
for presentation
Molecular tumor boards: Promise and reality
Elena Garralda
Spanish National Cancer Research Centre, Madrid, Spain
- Free
- slides video
- audio + slides
- All slides included
Characterization of antitumor activity of TAS6417, a novel EGFR-TKI targeting exon 20 insertions
Shinichi Hasako
TAIHO PHARMACEUTICAL CO., LTD., Tsukuba, Japan
- Free
- slides video
- audio + slides
- All slides included
EGFR-CD3 bispecific Probody™ therapeutic induces tumor regressions and increases maximum tolerated dose >60-fold in preclinical studies
Leila M Boustany
CytomX Therapeutics, South San Francisco, CA, United States
- Free
- slides video
- audio + slides
- All slides included
Neratinib has clinical activity in HER2-amplified breast cancer patients with tumors that have acquired activating mutations in HER2
Maurizio Scaltriti
Memorial Sloan-Kettering Cancer Center, New York, NY, United States
- Permission not
granted for presentation
Loss of the lysosomal transporter SLC46A3 is a mechanism for innate and acquired resistance to non-cleavable maytansine and pyrrolobenzodiazepine-based antibody-drug conjugates
Krista Kinneer
MedImmune, Gaithersburg, MD, United States
- Free
- Unknown permission
for presentation
AG-120 (ivosidenib), a first-in-class mutant IDH1 inhibitor, promotes morphologic changes and upregulates liver-specific genes in IDH1 mutant cholangiocarcinoma
Vikram Deshpande
Massachusetts General Hospital, Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Phase 1 study of the EZH2 inhibitor, tazemetostat, in children with relapsed or refractory INI1-negative tumors including rhabdoid tumors, epithelioid sarcoma, chordoma, and synovial sarcoma
Susan Chi
Dana-Farber Cancer Institute, Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
First in human, dose escalation trial of the combination of dabrafenib, trametinib, and navitoclax in patients with BRAF mutant solid tumors
Ryan J Sullivan
Harvard Medical School/MGH, Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Preliminary results from a phase 2 proof of concept trial of tipifarnib in tumors with HRAS mutations
Alan Ho
Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
Durable responses observed in recurrent high-grade glioma (rHGG) with Toca 511 and Toca FC treatment
Clark C Chen
University of Minnesota, Minneapolis, MN, United States
- Free
- Unknown permission
for presentation
Opening Remarks and Introduction
Judith S Sebolt-Leopold
Univ. of Michigan, Ann Arbor, MI, United States
- Free
- slides video
- audio + slides
- All slides included
Keynote Address
Margaret Foti
American Association for Cancer Research, Philadelphia, PA, United States
- Permission not
granted for presentation
Keynote Lecture: PI 3-kinase links obesity, insulin resistance, and cancer
Lewis C. Cantley
Meyer Cancer Center, Weill Cornell Medical College, New York- Presbyterian Hospital, New York, NY, United States
- Permission not
granted for presentation
Keynote Lecture: T-cell recognition of human cancer
Ton Schumacher
Netherlands Cancer Institute, Amsterdam, Netherlands
- Permission not
granted for presentation
Resistance to PD-1 blockade in MSI-H tumors
Luis A. Diaz
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
- Free
- podium video
- audio only
- Audio only
Genomic and neoantigen landscape of response and resistance to immune checkpoint blockade
Victor E. Velculescu
Johns Hopkins Kimmel Comp. Cancer Ctr., Baltimore, MD, United States
- Free
- podium video
- audio + slides
- Some slides withheld
Inactivation of DNA repair to improve immune surveillance
Alberto Bardelli
Univ. of Turin School of Medicine, Candiolo, Italy